Assessing the external validity of the VALIDATE-SWEDEHEART trial. (August 2021)

• Record Type: Journal Article
• Authors: Rylance, Rebecca T; Wagner, Philippe; Omerovic, Elmir; Held, Claes; James, Stefan; Koul, Sasha; Erlinge, David
• Is Part Of: Clinical trials. Volume 18:Number 4(2021)
• Page Start: 427
• Page End: 435
• Publication Date: 2021-08
• Subjects: VALIDATE-SWEDEHEART -- nationwide registry data -- real-world -- anticoagulants -- percutaneous coronary intervention; 615.5072405
• DOI: 10.1177/17407745211012438
• Languages: English
• ISSNs: 1740-7745

Abstract

Aims: The VALIDATE-SWEDEHEART trial was a registry-based randomized trial comparing bivalirudin and heparin in patients with acute myocardial infarction undergoing percutaneous coronary intervention. It showed no differences in mortality at 30 or 180 days. This study examines how well the trial population results may generalize to the population of all screened patients with fulfilled inclusion criteria in regard to mortality at 30 and 180 days. Methods: The standardized difference in the mean propensity score for trial inclusion between trial population and the screened not-enrolled with fulfilled inclusion criteria was calculated as a metric of similarity. Propensity scores were then used in an inverse-probability weighted Cox regression analysis using the trial population only to estimate the difference in mortality as it would have been had the trial included all screened patients with fulfilled inclusion criteria. Patients who were very likely to be included were weighted down and those who had a very low probability of being in the trial were weighted up. Results: The propensity score difference was 0.61. There were no significant differences in mortality between bivalirudin and heparin in the inverse-probability weighted analysis (hazard ratio 1.11, 95% confidence interval (0.73, 1.68)) at 30 days or 180 days (hazard ratio 0.98, 95% confidence interval (0.70, 1.36)). Conclusion: The propensity score difference demonstrated that the screened not-enrolled with fulfilled inclusion criteria and trial population were not similar. The inverse-probability weighted analysis showed no significant differences in mortality. From this, we conclude that the VALIDATE results may be generalized to the screened not-enrolled with fulfilled inclusion criteria.